| Research
Director - Dr. Daniel Cameron
top
Clinical
trial Expertise
| Glaxo |
1988 |
Lyme
disease |
| Ciba-Geigy |
1988
|
Hypertension
|
| Eli
Lilly |
1988
|
Hypertension
|
| Squibb |
1988-1989
|
Acute
bronchitis |
| G.D.
Searle |
1988-1989 |
Generalized
anxiety |
| Eli
Lilly |
1988-1989
|
Analgesic
(phase I, II) |
| UpJohn |
1989
|
Streptococcal
pharyngitis Uncomplicated urinary tract infection Wound and soft tissue
infection |
| Lyme Disease Practice and Research |
1997-2000
|
Lyme
Disease Surveillance Database |
| Pfizer |
2002-3 |
Gemini
study Clinical Utility study for Cholesterol and Hypertension Phase
IIIb Open labeled, multicenter trial |
| Columbia
|
2001-present |
Subinvestigator
NIH sponsered trial - Columbia |
| Lyme Disease Practice and Research |
1997-present
|
Lyme
Disease Retreatment Study |
| Lyme Disease Practice and Research |
2003-present
|
Validation
of Lyme treatment (VOLT) |
| Merck |
2003 |
Migraine
Therapy Evaluation Protocol Muli-center, open-label, crossover study
comparing Maxalt with usual care oral migraine medication |
| Genzyme |
2004 |
REACH
Program
An International Prosopective Observational Observational Registry
in Subjects at Risk Of Atherosthrombotic Events |
| Watson |
2004 |
MATRIX
Trial
Multicenter Assessment of Transdermal Therapy in Overactive Bladder
with Oxybutynin TDS |
top
Clinical
trial Experience
The
academic and clinical experience of the principal investigator for the
Lyme Disease Practice and Research is evident (see below). His capabilities and commitment
to serve as a mentor include his teaching capacity as assistant professor
Medicine in Geriatrics at the New York College of Medicine. His initial
master's defense in epidemiology, publications in delirium and dementia,
and 12 year history of scientific presentations at Lyme scientific conferences
are evidence of his commitment to an ongoing high quality patient-oriented
research. The ongoing research contributions sponsored by the Lyme Disease Practice and Research
demonstrate the evidence of monetary support for patient-oriented research.
Dr. Cameron's previous experience as an Assistant Professor and current
teacher for physicians, nurse practitioners, and physician assistants
demonstrates an ongoing mentor role. The 8-year series of oral and poster
presentations demonstrates the ongoing commitment as a leader in patient-oriented
research. The Lyme Disease Practice and Research director has provided leadership for the scientific
program and have final responsibility for the scientific, administrative,
and operational aspects of the project. The Director is responsible
for overall coordination and for development of the Lyme Disease Practice and Research as a
unique national resource.
Dr. Cameron remains active in the practice of medicine and admits patients
to Northern Westchester Hospital Center. He has published and presented
more than 30 scientific papers.
Research
History
After
a series of pilots over 5 years, a full scale Lyme disease Surveillance
Database was successfully launched. Over two thousand consecutive patients
with Lyme disease have been added consecutively to the Surveillance
Database since the inception of the cohort in June 1997. History, signs,
laboratory examinations, symptomology, and outcome data have been entered
prospectively on every patient.
The large sample size achieved by a Surveillance Database design in
a primary care setting tremendously increases the pool of patients for
study. The effect of race on Lyme disease was able to be examined for
the first time even though only 1% of the cohort was non-white - Blacks
(n = 65), Asian (n= 55) and Hispanic (n = 45). The impact of age on
Lyme disease was able to be examined for the young and old elderly (under
and over 80 years of age).
Patients have been identified quicker opening up the potential for more
rapid enrollment and lowering the cost of needed clinical trials. The
Surveillance Database was able to identify difficulties in the current
NIH trials by making the two-tier serologic criteria an entrance requirement.
Only 4 of the 1628 patients in the Surveillance Database met all of
the entrance criteria. Therefore, 24,000 patients with Lyme disease
would need to be screened to enroll 60 patients. top
|
